Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can aging and schizophrenia together worsen memory Self-Judgment?

NCT ID NCT03338179

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study investigates how aging and schizophrenia influence metamemory—the ability to judge one's own memory accuracy. Researchers will compare four groups: younger and older adults with schizophrenia, and younger and older healthy controls. Participants will rate their confidence in remembering word pairs, using both a generation strategy and a reading strategy. The goal is to see whether aging and the disease interact to impair this self-awareness more than either factor alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Judgement of learning evaluation (behavioral word-pair memory task)
What this could lead to
If successful, this could clarify how aging and schizophrenia separately and together affect self-awareness of memory, potentially guiding future cognitive support strategies.
What could go wrong
This is an observational behavioral study, not a treatment trial, so it won't directly change patient care. Results may not generalize beyond the specific word-pair task used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Feb 2011

Finished

May 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For both: * Age: between 18 and 45 years for adults, and 59.55 and above for older, For patients : * DSM-5 criteria of schizophrenia * Adult patients (\<45 years) will be matched to elderly patients (\> 59.55 years) gender and educational level, * Patients followed as outpatients, * Age of onset of the disease less than 40 years, * Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month * Not more of a benzodiazepine, * Patients on protection of justice or not, For controls : * \- Matched for sex to patient * Age-matched (+/- 3 years) to patient * Matched for educational level (+/- 2 years) to patients Exclusion Criteria: * -For patients : * Any other comorbid psychiatric diagnosis of Axis I DSM-5 (particularly depression, addiction excluding tobacco, dementia) * Patients with impaired vision or hearing preventing the realization of the tests. * Long-term Anticholinergic treatment. * Patients with less 5 years of school For controls: * Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco) * Head injuries, brain injuries or diseases, * vision or hearing problems preventing the realization of the tests. * Current or past addiction to all toxic substances except tobacco. * Long-term Anticholinergic treatment. * Related to the first degree diagnosed with a psychotic disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Schizophrenia

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.